Logo Image
Business
Practice ManagementMalpractice ConsultHealth Law & Policy
Media
Case-Based Peer PerspectivesInvestigator Perspectives Medical World NewsPodcastsUrology Medical PerspectivesUTv VideosPeer ExchangeSpecial ReportVirtual Tumor BoardClinical Forum InsightsInsightsMedcastPeers & PerspectivesShorts
Conferences
Conference ListingConference Previews Conference Recaps
Publications
Urology Times JournalEditorial Advisory BoardUrologists in Cancer CareSupplements and Featured PublicationsClinical Forums Recaps
More
CME/CE
Resources
Begin Your Journey: Tackling BurnoutSponsored MediaLive EventsInteractive ToolsJob BoardPartnersSponsored ResourcesTreatment Landscape Evolutions

Subscribe

  • Business
  • Media
  • Conferences
  • Publications
  • CME/CE
  • Resources
  • Subscribe
  • Benign Conditions
  • Benign Prostatic Hyperplasia
  • Bladder Cancer
  • Female Urology
  • Genitourinary Cancers
  • Genomic Testing
  • Hormone Therapy
  • Kidney Cancer
  • Kidney Stones
    • Challenging Anatomy
  • Men's Health
  • Next-Generation Imaging
  • OAB and Incontinence
    • Voiding Dysfunction
  • Pediatrics
  • Prostate Cancer
    • Controveries in Urologic Cancer
    • Drug Therapy
  • Sexual Dysfunction
  • UTUC
  • Urologic Surgery
    • Cosmetic Surgery
Spotlight -
Peer Exchange|
Peers and Perspectives|
Case-Based Peer Perspectives|
Urology Times Journal
Advertisement

Elizabeth Pan, MD

Advertisement

Articles by Elizabeth Pan, MD

GNRH agonists vs antagonists in prostate cancer: How to choose

ByElizabeth Pan, MD,Rana R. McKay, MD
June 10th 2021

Many factors play into decision-making process when weighing agents.

Advertisement

Latest Updated Articles

  • GNRH agonists vs antagonists in prostate cancer: How to choose
    GNRH agonists vs antagonists in prostate cancer: How to choose

    June 10th 2021



Advertisement
Advertisement

Trending on Urology Times

1

Ac-225 rosopatamab tetraxetan shows promising activity in Lu-PSMA–pretreated mCRPC

2

The UroOnc Minute: Perioperative Treatment for High-Risk Localized Prostate Cancer, With Keyan Salari, MD, PhD

3

Sanoj Punnen, MD, on balancing ADT efficacy with cardiovascular safety

4

FDA grants tentative approval to generic enzalutamide tablets

5

Advancing PROs to support survivor-centered NMIBC care

  • About Us
  • Advertise
  • Editorial
  • Contact Us
  • Job Board
  • Terms and Conditions
  • Privacy
  • Do not sell my Personnal Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

  • Contagion Live
  • CGT Live
  • Neurology Live
  • HCP Live
  • Oncology Live
  • Contemporary Pediatrics
  • Contemporary OBGYN
  • Urology Times
  • The Educated Patient
  • Patient Care Online
HCP Live Network
Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us